Broad-spectrum agents for flaviviral infections

Dengue, Zika and beyond

Veaceslav Boldescu, Mira A.M. Behnam, Nikos Vasilakis, Christian D. Klein

Research output: Contribution to journalReview article

64 Citations (Scopus)

Abstract

Infections with flaviviruses, such as dengue, West Nile virus and the recently re-emerging Zika virus, are an increasing and probably lasting global risk. This Review summarizes and comments on the opportunities for broad-spectrum agents that are active against multiple flaviviruses. Broad-spectrum activity is particularly desirable to prepare for the next flaviviral epidemic, which could emerge from as-yet unknown or neglected viruses. Potential molecular targets for broad-spectrum antiflaviviral compounds include viral proteins, such as the viral protease or polymerase, and host targets that are exploited by these viruses during entry and replication, including α-glucosidase and proteins involved in nucleoside biosynthesis. Numerous compounds with broad-spectrum antiviral activity have already been identified by target-specific or phenotypic assays. For other compounds, broad-spectrum activity can be anticipated because of their mode of action and molecular targets.

Original languageEnglish (US)
Pages (from-to)565-586
Number of pages22
JournalNature Reviews Drug Discovery
Volume16
Issue number8
DOIs
StatePublished - Jul 31 2017

Fingerprint

Flavivirus Infections
Glucosidases
Flavivirus
West Nile virus
Virus Internalization
Dengue
Viral Proteins
Virus Replication
Nucleosides
Antiviral Agents
Peptide Hydrolases
Viruses
Infection
Proteins
Zika Virus

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Broad-spectrum agents for flaviviral infections : Dengue, Zika and beyond. / Boldescu, Veaceslav; Behnam, Mira A.M.; Vasilakis, Nikos; Klein, Christian D.

In: Nature Reviews Drug Discovery, Vol. 16, No. 8, 31.07.2017, p. 565-586.

Research output: Contribution to journalReview article

Boldescu, Veaceslav ; Behnam, Mira A.M. ; Vasilakis, Nikos ; Klein, Christian D. / Broad-spectrum agents for flaviviral infections : Dengue, Zika and beyond. In: Nature Reviews Drug Discovery. 2017 ; Vol. 16, No. 8. pp. 565-586.
@article{4e9102e11958438985ba5ebf415f72ac,
title = "Broad-spectrum agents for flaviviral infections: Dengue, Zika and beyond",
abstract = "Infections with flaviviruses, such as dengue, West Nile virus and the recently re-emerging Zika virus, are an increasing and probably lasting global risk. This Review summarizes and comments on the opportunities for broad-spectrum agents that are active against multiple flaviviruses. Broad-spectrum activity is particularly desirable to prepare for the next flaviviral epidemic, which could emerge from as-yet unknown or neglected viruses. Potential molecular targets for broad-spectrum antiflaviviral compounds include viral proteins, such as the viral protease or polymerase, and host targets that are exploited by these viruses during entry and replication, including α-glucosidase and proteins involved in nucleoside biosynthesis. Numerous compounds with broad-spectrum antiviral activity have already been identified by target-specific or phenotypic assays. For other compounds, broad-spectrum activity can be anticipated because of their mode of action and molecular targets.",
author = "Veaceslav Boldescu and Behnam, {Mira A.M.} and Nikos Vasilakis and Klein, {Christian D.}",
year = "2017",
month = "7",
day = "31",
doi = "10.1038/nrd.2017.33",
language = "English (US)",
volume = "16",
pages = "565--586",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Broad-spectrum agents for flaviviral infections

T2 - Dengue, Zika and beyond

AU - Boldescu, Veaceslav

AU - Behnam, Mira A.M.

AU - Vasilakis, Nikos

AU - Klein, Christian D.

PY - 2017/7/31

Y1 - 2017/7/31

N2 - Infections with flaviviruses, such as dengue, West Nile virus and the recently re-emerging Zika virus, are an increasing and probably lasting global risk. This Review summarizes and comments on the opportunities for broad-spectrum agents that are active against multiple flaviviruses. Broad-spectrum activity is particularly desirable to prepare for the next flaviviral epidemic, which could emerge from as-yet unknown or neglected viruses. Potential molecular targets for broad-spectrum antiflaviviral compounds include viral proteins, such as the viral protease or polymerase, and host targets that are exploited by these viruses during entry and replication, including α-glucosidase and proteins involved in nucleoside biosynthesis. Numerous compounds with broad-spectrum antiviral activity have already been identified by target-specific or phenotypic assays. For other compounds, broad-spectrum activity can be anticipated because of their mode of action and molecular targets.

AB - Infections with flaviviruses, such as dengue, West Nile virus and the recently re-emerging Zika virus, are an increasing and probably lasting global risk. This Review summarizes and comments on the opportunities for broad-spectrum agents that are active against multiple flaviviruses. Broad-spectrum activity is particularly desirable to prepare for the next flaviviral epidemic, which could emerge from as-yet unknown or neglected viruses. Potential molecular targets for broad-spectrum antiflaviviral compounds include viral proteins, such as the viral protease or polymerase, and host targets that are exploited by these viruses during entry and replication, including α-glucosidase and proteins involved in nucleoside biosynthesis. Numerous compounds with broad-spectrum antiviral activity have already been identified by target-specific or phenotypic assays. For other compounds, broad-spectrum activity can be anticipated because of their mode of action and molecular targets.

UR - http://www.scopus.com/inward/record.url?scp=85016393116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016393116&partnerID=8YFLogxK

U2 - 10.1038/nrd.2017.33

DO - 10.1038/nrd.2017.33

M3 - Review article

VL - 16

SP - 565

EP - 586

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 8

ER -